You have no items in your shopping cart.
Cancer Highlights
A decision support tool to optimize your cancer pipeline portfolio. From research and development to Market. Cancer Highlights™ is BioSeeker Group’s flagship decision support tool, for portfolio assessment and planning of cancer drug development. Cancer Highlights™ uses standardized criteria in a five pillar assessment to compare drug development strategies in oncology, making it easy to find and compare analysis not only within one single Cancer Focus Area but also between different areas.
| Items 1 to 10 of 47 total | Page: | Show per page |
| View as: List Grid |
Sort by
|
Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
Published by BioSeeker Group on Jun 24th, 2010
€ 2,450.00
This report identifies the competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and significant. Learn More
A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market
Published by BioSeeker Group on May 24th, 2010
€ 1,950.00
This report comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. The report extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer. Significantly new prostate cancer therapies will soon come to challenge old established drugs on the market. Four out of five target strategies in Phase III and nine out of ten in Phase II are novel and innovative in their design. Learn More
Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place
Published by BioSeeker Group on Apr 26th, 2010
€ 1,950.00
This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer. Significantly new breast cancer therapies will soon come to challenge old established drugs on the market. Learn More
Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?
Published by BioSeeker Group on Mar 23rd, 2010
€ 1,950.00
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in pancreatic cancer. Learn More
Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?
Published by BioSeeker Group on Mar 1st, 2010
€ 2,450.00
This report comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. The report extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target profiles, and assesses them in 69 different cancer indications. Learn More
Analytical Tool - Leukemia
Published by BioSeeker Group on Jan 20th, 2010
€ 3,100.00
A unique tool for analyzing the complex competitive pressure within the different fields of leukemia therapeutics. Learn More
Apoptotic Therapeutics in Oncology - Where to Commercialize?
Published by BioSeeker Group on Nov 30th, 2009
€ 2,450.00
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning. Learn More
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published by BioSeeker Group on Oct 29th, 2009
€ 2,450.00
This report is an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More
Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning
Published by BioSeeker Group on Aug 25th, 2009
€ 2,450.00
This report is an important part of creating and implementing a market development plan for any lung cancer therapeutic drugs to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More
Lymphoma Drug Development Strategies at Work - Define Your Competition
Published by BioSeeker Group on Jun 22nd, 2009
€ 1,950.00
This report will be an important part of creating and implementing a market development plan for any lymphoma therapeutic drug to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More
| Items 1 to 10 of 47 total | Page: | Show per page |
| View as: List Grid |
Sort by
|